research and possibly search for new parameters of the ILP activity are needed

Disclosure of Interests: None declared **DOI:** 10.1136/annrheumdis-2019-eular.3735

FRI0589

IS THERE AN OVERLAP OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIDES WITH IGG4-RELATED DISEASE OR NOT?

Abdulsamet Erden, Ertuğrul Çağrı Bölek, Gözde Kübra Yardımcı, Şule Apraş Bilgen, Omer Karadag, Hacettepe University Vasculitis Centre, Hacettepe University Vasculitis Center, Ankara, Turkey

Background: Pseudotumor orbita, pachymeningitis, periaortitis could be seen in both ANCA-associated vasculitis and IgG4-RD. Sometimes it may be difficult to differentiate these two entities. The co-occurrence/concurrence of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) and IgG4-related disease (IgG4-RD) was recently published by a collaborative EUVAS group [1].

Objectives: Firstly, we aimed to investigate ANCA positivity of our IGG4-RD cohort. Secondly, a literature review of co-occurrence/concurrence of AAV and IgG4-RD was done.

Methods: Data of totally 62 patients with IgG4-RD in Hacettepe Vasculitis Center Database was used. Patients were diagnosed with IgG4-RD according to comprehensive diagnostic criteria [2]. Dataset of patients including demographic data, clinical characteristics, and imaging and laboratory findings of IgG4-RD was re-evaluated in terms of AAV and ANCA test

At next step, we performed a systematic literature review of the PUBMED database covering the time period until April 2018. Relevant publications were searched using the MeSH terms "IgG4-related disease and Eosinophilic Granulomatosis with Polyangiitis", "IgG4-related disease and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" and "IgG4-related disease and Granulomatosis with Polyangiitis".

Results: Totally 29 (46.7%) of our patients had ANCA results. Out of 29 patients 15 (51.7%) were considered as probable, 10 (34.5%) as definite and 4 as possible (13.8%) for IgG4-RD. Three (10.3%) of these patients had ANCA positivity. All of these ANCA titers were in low degree positivity (MPO-ANCA 1/100, MPO-ANCA 1/32 and PR3 ANCA 1/100). These three patients didn't have any findings of vasculitis and didn't have granuloma in their biopsy. When we evaluate these three patients with regards to meeting the Ig G4- RD criteria, 1 was definite, 1 was probable and 1 was possible.

In literature review, we found 17 cases that having both features of IgG4-RD and AAV (Table). These cases were re-evaluated according to the 'Comprehensive Diagnostic Criteria for IgG4-RD'. Diagnoses of IgG4-RD were definite in 11 cases (64.7%), probable in 2 cases (11.8%) and possible in 4 cases (23.5%). ANCA were positive in 15 of 17 patients (88%). ANCA were directed against proteinase 3 (PR3-ANCA) in 6 patients and were directed against myeloperoxidase (MPO-ANCA) in 5 patients. Other four cases had both MPO-ANCA and PR3-ANCA. All PR3-ANCA positive cases have high titers of ANCA, whereas only one MPO-ANCA positive case has high titers of ANCA.

Conclusion: None of our IgG4-RD patients have any overlap with ANCA-associated vasculitis. Only in 3 patients (10.3%), ANCA positivity was detected without any histopathologic evidence. Just two patients of literature review, seemed to be full compatible with both diseases. Even though ANCA-associated vasculitis and IgG4-RD share clinical features, we think this might be as co-occurrence instead of a histopathologic link.

REFERENCES:

- [1] Danlos, FX. Autoimmun Rev, 2017.
- [2] Umehara, H. Mod Rheumatol, 2012.

Disclosure of Interests: None declared **DOI:** 10.1136/annrheumdis-2019-eular.6130

_	labi	e. Di		ution o	ii beilii	ographic,	Cilli		tures	s III Seve	ntee		its a	Liter	ature	_	_
Paulus et al.	Tošovský et al.	Kotani et al.	Drobyshaa et al.	Ohno et al.	Mosey et al.	Mahor et il.	Bravais et al.	Alexandski et al	ë S.	Ayuzama et al.	Hanioka et al.	Della-Tome et al.	Youge et al.	iguchi et al.	Saksiri et al.	Popkirow et al.	70000
8, M	67,M	3,42	13,0	31.0	70, M	ž	31.7	'n,	42, M	64, 5	72, M	2,5	61, M	ž	10, M	S2, M	×
Cefale (Cles: + Boyey + Levelof (gG4)	Definite (Ciric + Bopsy + Level of 1gG4)	Positie (Ciric + Level of IgG4)	Probable (Clnic + Bopsy)	Ciric + Bopsy + Level of IgG4)	Definite (Ciric + Biopsy + Level of Ig G41)	Definite (Cinic + Biopsy + Level of (g.64?)	Definite (Clric + Bopsy + Levelof (gG4)	Cinic + Bopsy + Level of IgG4)	Definite (Ciric + Bopsy + Level of 1gG4)	Positie (Cloic + Level of (g64) (Bopsy criteria is not obtainable)	Definite (Ciric + Bopsy + Level of IgG4)	Definite (Ciric + Biopsy + Level of IgG4)	Cefnic (Ciric + Bopsy + Level of 1gG4)	Positie (Cirk: + Level of IgG4)	Gefinite (Claic + Bopsy + Level of 1gG4)	Probable (Clnic + Bopsy)	does no sector on con-
Orbita Blopsy: No findings in favor of AAALThyrightons and monotonal plasma cell. Densel ymphrydainnacyd c'effitistes and fibrosis - ligGA/lgG+ pharma cell sisto od 50,3%	Mediastrial Mara Rippy: Soritimn Brass, %50 flams cell (gd positive, ito vacalité s'etile); Midney Biopy: Acité foc à regmental necostàtig paus-immunejionn eukonphrits in mavy glomes lus cellular crassoris	Naual polyp (prior to the application): Without growtomatous and vaysal to, charges, chronic inflammation with lymphocyte and plasmacell inflitration, gG4 rate unknown.	Bye Bid: Nubinuclear glant cells, mised inflammestory cells, granulomatous and necrolating vesculats, fibrinoid necrosis, IgG4/IgG ratio, %5.0	this day contab biopsylmad macaat, invite plannancy is cellstanou, suntiem fisousi, glici (3),975 glickly (ginao, 43%), No-MCC, volusi (bir for legic). 43%), No-MCC, volusi (bir for legic). 438%, No-MCC, volusi (bir for le	Dana Biogoy Sandom fibrasi, Nepetrisphic fibraticitisue 1954 statined phorms cell > 50 HPT, No granuloma.	Noral Bioppy. Noral Bioppy in the probability of t	Vocal cord granulema: Superfidal information for diagnosis cellisient tungs Storiform (boosis, plasmool infiltration, appl pitama >/A20 (HPF)	Side Bild ppyr Lokalophociaes cosculis: Reseabulibet biology Coxocotom with IgG4-90, IgG4+/IgG+ plasma >450	Kidney Biopsy: Claccomatid on, cellulay residess, perigioneroniar galunoma formation, in the field of Islanb- Intentitial; massive (jump begge and glaem cell inflamion, typisk/ typis ylaema সাধ্বয়	Aldray Keper (giA-ly) (pipulama (s) 0 Aleria Paraous gi arres (popular) (s), a localesca Sal neghrita, cosionphi (r) Aleria Barpa (s) sirephi Soriesphi Comenta, lua localesca Sal neghrita, rosionphi (s) Sal a Barpa (s) sirephi Soriesphi Comenta, lua localesca (s) (s), a localesca (s), a locales	Sán Bepay: Loukogasciasi cusculis with osirogál infiltration. Nasil Muco a Bapay: (gC4 positive plarmoște vecosirophil, sodform fib rods, igC44/ (gC4 plarma >1/40).	Lacinal Gland Stollorin Horse, Imprincplannos(cicilaba), 1964/1961-statina -4966. No vasculatis Indrag Cerpaniulam. No vasculatis Indrag Cerpaniulam. Lacinal Gland Stollorin Horse	Transbronchial lung biops; influrmatory granuloms, lymphocyte and plasma cell inflitation, >2.0 lgGd-positive plasma cell (inPF)	Orbital tumor storapy. Neurophi and knyslocysterifibration est. 1gG4 Pocificy (IgSpoziare etis), bu plotebis, Althougher is no extence of practions, rupture of duzic tumina arosy wait of assic tumina excusor. Laination and few part cell were do proved.	Kidney Biopyfoleving sterold; Tubulonos: tida rephritis, Įvmphoqee and plasma cel infiltration, Įg64 Positier/ §65 positiever 5/0, maleokularantery fatnada rezorosi. Parodis: Biopay: Wartin turnor + Įg64, Įg64 Posthier/ Įg6 = 15/0.	Menina Bopay. Dense plasmacel infiltration	
No supportive finding	Supportive likiting-biggsy and AAVCA positivity	No direct findings in support of wooda's except prioritibitary of strustes.	Non supportive PAKCs Ray and urine tests Nowever biopsy findings are compatible with both AVV and IgG4-IID	No vascultis findings in the organs	No Systemicvazults fireings (Ne K.B., AC, Renal) No Germilema	(Mod available)	Billatest vocal cord granuloma	Ne-daller lang leitors and fina find plass lickly supports ANA verycallys. Leukocypactualist-vascul its may of their bedieved upded after RX (this can also be serum disease) or may also articled very data fine course of vasculitis. High level of acuterphase reactant also supports vasculitis.	EEPA, Gommu bregettis, pergi ornealir grandomata formation, discret parasali sinusitis, MPO-AACA, and oo sho phila	WRC 2 DOIGN'H, Claireph I 3504 Okies. BMG Right median nerie neuropathy, Hewever, no crescents or necroticing glosserulo rephilitis.	31.3% osiniqnik (2.50 jul.) 8E-454 lülmi. DMC: Multiple mononeuropathy, in CT thickering in resal mucosa	in right lang? roundlimited/institisted notleaend cavitary (blace) mass, spannentobal lesion on the right of 15 and 16 wretens (FCG) insolvement in PET-CT) Biopsy supports the findings.	No Clinical specification were given except Granuloma.	In CT no nodelia Islian Inthe lurgs. 8 opy fiedings, AACA positivity, improvement after CYC treatment	In PETCT no vacular involvement bowere with epideritis and kidney biopay and high level of C-RP supports the diagnosis of vaccule's.	In cerebral anglegosphy rovasculitis in the bioppy no granulematious inflammation.	Constitution of the Consti

EDIOEOO

UVEITIS SECONDARY TO CHECKPOINT INHIBITORS

JAVIER GARCÍA, Eugenio Perez-Blazquez. HOSPITAL 12 DE OCTUBRE, MADRID, Spain

Background: The introduction of immunotherapy (immune checkpoint inhibitors, ICI) has led to a revolution in oncological treatments. The inhibitors of CTLA4 (ipilimumab), of PD1 (pembrolizumab, nivolumab) and of the ligand of PD1 (atezolizumab, avelumab, durvalumab) regulate T activation and its effector function, being effective for the treatment of various types of cancer¹. However, this effect leads to a series of immune-mediated adverse events, among which uveitis of autoimmune mechanism have been described in about 1% of treatments².

Objectives: Methods: descriptive study of retrospective review of the cases of a tertiary hospital with about 1000 treatments between the beginning of 2014 and the end of 2018.

Results: A series of 4 cases of uveitis of autoimmune origin associated with ICI is presented (see table). The series described has characteristics similar to the information previously reported in the literature2, with an incidence of around 0.4%, according to the previously described, with frequencies of ocular toxicity around 1%, being the uveitis is the most frequent form of presentation. The time of presentation of uveitis since the beginning of treatment has been in all cases in the first 6 months. The forms of presentation described before, ranges from anterior uveitis (AU) to panuveitis and often papilledema, usually bilateral, as are all those described in our series. In addition, 50% are AU (grade 2) and the other 50% panuveitis with papilledema (grade 3). In all the cases described, treatment was interrupted, a half it could be reintroduced without recurrence of uveitis. All the patients received topical treatment, the more severe systemic corticosteroids at doses of 0.5-1 mg/kg in accordance with the recommendations. The final prognosis was good, with preservation of VA in all cases, and topical and systemic treatment could be withdrawn in all patients. A patient treated with Ipilimumab presented synechiae as a complication.